INVICTUS ANNOUNCES APPOINTMENT OF INTERIM CEO AND ALTERNATE DIRECTOR

Vancouver, B.C., Oct. 08, 2019 (GLOBE NEWSWIRE) — Vancouver, BC, October 8, 2019 – INVICTUS MD STRATEGIES CORP. (“Invictus” or the “Company”) (TSXV: GENE; OTCQX: IVITF; FRA: 8IS2) announces that, due to health complications, Trevor Dixon, President, CEO and Director of the Company, is unable to fulfill his duties to the Company for the time being.  Accordingly: (1) the Board has appointed Marc Ripa as Interim CEO; and (2) Mr. Dixon has appointed Brenda Dixon to be his alternate as a Director of the Company.  Mr. Ripa currently serves as COO of the Company and Ms. Dixon currently serves as a director of Acreage Pharms Ltd., a wholly owned subsidiary of the Company.  The appointments will remain in effect until further notice. For more information, please visit www.invictus-md.com. Marc RipaInterim Chief Executive Officer Investor Relations 1-844-800-6086E-Mail: connect@invictus-md.com Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. About Invictus Invictus is a global cannabis company with a focus on the Canadian cannabis space, offering a selection of products under a wide range of cannabinoid profiles that fit the demand of the Company’s medical clients and retail customers. The Company’s integrated sales approach is defined by five pillars of distribution including medical, adult-use, international, Licensed Producer to Licensed Producer and sales to provinces. To meet growing demand, Invictus is expanding its cultivation footprint with two cannabis production facilities licensed under the Cannabis Act, which replaced the Access to Cannabis for Medical Purposes Regulations in Canada. Invictus’ wholly-owned subsidiary Acreage Pharms Ltd.’s (“Acreage”) Phase I and Phase II facilities are in full production. Acreage is awaiting the amendment to their license from Health Canada to include the Phase III facility. AB Laboratories Inc., a company which is a 50% owned subsidiary of Invictus has completed its Phase II expansion and received its amended license from Health Canada. Another of Invictus’ wholly owned subsidiaries, 2015059 Alberta Ltd. (dba Leaf Wise), continues to connect medical clients to physicians for medical cannabis and to Invictus’ fully licensed cannabis producers under the Cannabis Act. Invictus is targeting up to 50 percent of production to medical cannabis. Invictus drives sustainable long-term shareholder value by continuing to develop Invictus’ Canadian production of medical and recreational cannabis products. For more information visit www.invictus-md.com. Kathy Love
Invictus kathy@invictus-md.com

CBJ Newsmakers

Recommended
Chakana Engages European Corporate Communications ConsultantLibrestream Announces Deployment of Onsight Connect to FPSO ‘BW Catcher’ in the North Sea